Flu, Season, Diseases Affect Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Flu, Season, Diseases Affect Trials Plan ahead for many seasonal diseases that could derail even the best laid clinical trials.

Source: Applied Clinical Trials



Seasonal variation in the incidence of diseases has been observed for centuries, dating back at least to ancient Greece, and yet scientific understanding of its underlying mechanisms remains relatively rudimentary for many diseases.1 Seasonality is not only an important factor in common infectious diseases—such as influenza, chickenpox, and measles—but also in noninfectious diseases such as seasonal affective disorder (SAD) and rheumatoid arthritis (RA).



Place that next to clinical development, which at the best of times is a complex, long, frustrating process in an ever-changing regulatory environment, and you have an unenviable task for clinical trial managers. Clinical trial managers must make considerable logistical decisions and need significant depth of knowledge, including but certainly not limited to: planning timelines and projecting and managing budgets whilst at the same time ensuring the delivery of a high-quality product. However, management for seasonal diseases adds to this complexity in regard to fluctuations in the incidence of the disease studied; the recruitment of patients to coincide with a particular part of the year (dependent on latitude, of course); and the attentiveness to unexpected changes in the pattern of the disease and their implication on the running of the clinical trial.

Mathematical modelling has provided the advancement necessary to take the hypotheses of seasonality and apply them to the field. Nevertheless, given the complexity of seasonality, a serious limiting factor to quantitative analyses and predictive models of disease patterns is the lack of long-term disease records with similar data collected over a network of spatial locations.2

There are a multitude of complexities associated with running a clinical trial where a seasonal disease is the target, or could impact the trial itself. But there are strategies that can allow for the control and quality seen in less complex trial management to be transferred to the ever variable field of seasonal diseases [see sidebar].

Incorporating seasonality

The planning and management of timelines are key to successfully running a seasonal clinical trial. This includes from drafting the study design through document submissions and patient recruitment, to the trial itself. Teams employed must be focused, efficient, and resourceful, as well as fully trained in the indication studied and its seasonality.

This section focuses largely on the discussion of infectious diseases. Ultimately, noninfectious diseases such as seasonal allergies are much more predictable, and the principles discussed here can be easily applied. However, the challenges arise when dealing with infectious diseases where seasonality can be much more volatile and where trial management must be both robust and flexible.


Top 5 Seasonal Diseases in Brief
Regional profiles also need to be applied when managing the global trial. Standard geography subdivides the earth into regions by latitude and there are seasonal disease fluctuations between these regions. Data for seasonal influenza, for example, can be accessed from the World Health Organization's (WHO) FluNet site, which collates global influenza data for the purpose of disease information and forecasting.

Recruitment, planning, and timelines

It is common knowledge that almost 50% of delays in trials are a result of problems with subject recruitment.11 Naturally, subject recruitment for a seasonal clinical trial needs to be completed before the studied indication reaches its peak incidence (e.g., for indications with short seasons), and perhaps even before the increase in incidence begins if the study is to be carried out over the duration of the season.

This alone raises issues. If one is recruiting patients for a seasonal indication, before that indication is evident, how can a site determine whether a patient will meet the inclusion criteria? For some indications, such as seasonal allergic rhinitis, inclusion could be based upon the patient's medical records, but for an indication such as influenza there is no way of knowing who will contract the virus. In these cases, there needs to be a rapid recruitment program in place, to enroll patients as soon as the disease is diagnosed. It would then be wise to select sites with the capabilities to recruit larger numbers of patients within short time frames.

Conducting detailed feasibility for such diseases requires a thorough review of the incidence of the disease in previous seasons and an assessment of the factors that influenced its incidence (e.g., particularly low winter temperatures). It is also of utmost importance to submit the trial to additional countries, as a delay of one month in obtaining regulatory approval in a single country could potentially set the trial back by six months. The luxury of extending the patient recruitment period for this type of trial is simply not available.

Study design planning, protocol writing, site selection, and investigator training need thorough attention regarding indication awareness, project management, and time management. In particular, the following should be noted:

  • It is paramount to know the peak incidence and peak timing of the indication in different countries/regions, as this may vary considerably within a continent/hemisphere.
  • The choice of participating countries/regions should be carefully selected so that regions with different timings of peak incidences and with a high probability of meeting the expected timelines can be included.
  • The start-up should be carried out in phases, that is, not all regions at the same time. The aim would be to activate and give priority to those regions that have the seasonal peak sooner and direct all resources toward that region/country, followed by those regions with a later peak. This must involve careful project management because the regions will be in different phases: start-up, recruiting, and recruitment almost exhausted.
  • Contingency plans should be put in place, taking into account that if at the beginning of the study the estimated predictions are not met, contingency plans are available that offer other regions for recruitment and options of different seasonal peaks—occurring later or lasting longer. The opposite situation may also occur, though less often: If recruitment expectations at the first sites initiated are exceeded and global recruitment is therefore able to end sooner than expected, additional resources/budget may have been wasted on open countries/sites with different seasonal peaks that will not ultimately be opened.

Document submissions

With subject recruitment timing being such a key factor, it will be essential to submit clinical trial documents to the Ethics Committee (EC)/Competent Authority (CA) in good time in order to receive approval of a trial before the planned start of subject recruitment. Certainly in the northern hemisphere, EC/CA members, investigators, and patients tend to be on vacation during the summer months, and clinical trial approvals (as well as investigator contract approvals and patient recruitment) are therefore delayed over this time. Submissions must be timed in coordination with the EC/CAs, even if it means early submission in order to guarantee trial set-up timelines are met.

Mathematical models and surveillance programs

Mathematical models of infectious diseases have contributed significantly to scientific understanding of the dynamics of epidemics as they spread through large populations.12

The traditional model used is the SIR (susceptible-infected-resistant) model.13 This model comprises Susceptible individuals (S), Infected individuals (I), and Removed individuals (R). Each individual begins in the susceptible class, only to move to the infected class after coming into contact with an infected person. Infected individuals eventually recover from the disease and move on to the recovered class. Being "recovered" and unable to be infected once again, they are essentially removed from the population and play no further role in the dynamics. Epidemics are continuously fueled by the constant supply of new susceptibles that arise due to the birth of new individuals.19

Essentially the SIR model is basic and does not account for the many factors that influence seasonal diseases. More recently, these factors have been incorporated, including seasonality and "skipping dynamics," the principles of which yield promising forecasting tools,18,19 which have the potential to be used for managing seasonal trials. Mathematical models have downfalls, as nature is never predictable, even if incorporating so-called chaos factors. For one particular season, the model may be way off mark, and trial start-up and progress based on such a model would be thrown out of sync with the disease incidence.

Throughout the world there are a multitude of communicable disease surveillance programs coordinated by bodies such as the WHO, the Health Protection Agency, and the Centers for Disease Control and Prevention. Communicable disease surveillance is the continuous monitoring of the frequency and distribution of disease and death due to infections that can be transmitted from human to human or from animals, food, water or the environment to humans, and the monitoring of risk factors for those infections.

Significantly, an important part of communicable disease surveillance is to detect the occurrence of outbreaks or epidemics so that immediate action can be taken to identify and control the source (e.g., outbreaks of food poisoning) or so that the health service is prepared to deal with increased numbers of patients (e.g., in a flu epidemic).19

When managing a seasonal study, it is important to maintain good communication with the local, national, and international surveillance networks, to time study start up appropriately.

Mathematical modelling and disease surveillance are intricately linked in the monitoring and control of communicable diseases, and it would be a serious omission on the clinical trial manager's behalf if these vast resources were not utilized in the planning and conduct of a seasonal trial.

Conducting seasonal clinical trials is certainly complex, involving intricate time management and disease forecasting requirements. Full planning is paramount, and it has been seen that flexible patient recruitment, site selection, and document submission plans are necessary for a successful seasonal clinical trial.

Yamin Khan*, PhD, is executive vice president, Clinical Development for Pharm-Olam International, email:
. Sarah Tilly is a medical writer for Pharm-Olam International, The Brackens, London Road, Ascot UK SL5 8BJ.

*To whom all correspondence should be addressed.

References

1. M. Lipsitch and C. Viboud, "Influenza Seasonality: Lifting the Fog," Proceedings of The National Academy of Sciences, 106 (10) 3645-3646 (March 10, 2009).

2. M. Pascual and A. Dobson, "Seasonal Patterns of Infectious Diseases," PLoS Medicine, 2 (1) e5 (January 2005).

3. FluNet, the World Health Organisation Communicable Disease Global Atlas, http://gamapserver.who.int/GlobalAtlas/DataQuery/viewData.asp|~http://gamapserver.who.int/GlobalAtlas/DataQuery/viewData.asp .

4. D.P. Skoner, "Allergic Rhinitis: Definition, Epidemiology, Pathophysiology, Detection, and Diagnosis," Journal of Allergy and Clinical Immunology, 108 (1) S2-S8 (July 2001).

5. A.S. Kemp, "Allergic Rhinitis," Paediatric Respiratory Reviews, 10 (2) 63-68 (June 2009).

6. L.N. Rosen, S.D. Targum, M. Terman et al., "Prevalence of Seasonal Affective Disorder at Four Latitudes," Psychiatry Research, 31 (2) 131-144 (1990).

7. S.A. Morrissey, P.T. Raggatt, B. James et al., "Seasonal Affective Disorder: Some Epidemiological Findings from a Tropical Climate," Australia and New Zealand Journal of Psychiatry, 30 (5) 579-586 (1996).

8. N. Iikuni, A. Nakajima, E. Inoue et al., "What's in Season for Rheumatoid Arthritis Patients? Seasonal Fluctuations in Disease Activity," Rheumatology, 46 (5) 846-848 (2007).

9. H. Aikman, "The Association Between Arthritis and the Weather," International Journal of Biometeorology, 40 (4) 192-199 (1997).

10. A. Fleming, J.M. Crown, M. Corbett, "Early Rheumatoid Disease," Annals of Rheumatic Disease, 35, 357-360 (1976).

11. R.M. Anderson and R.M. May, Infectious Diseases of Humans: Dynamics and Control (Oxford University Press, New York, 1991).

12. L. Stone, R. Olinky, A. Huppert, "Seasonal Dynamics of Recurrent Epidemics," Nature, 446 (7135) 533-536 (2007).

13. Health Protection Agency, "Surveillance," http://www.hpa.org.uk/webw/HPAweb&Page&HPAwebAutoListName/Page/1158313434400?p=1158313434400|~http://www.hpa.org.uk/webw/HPAweb&Page&HPAwebAutoListName/Page/1158313434400?p=1158313434400 .

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here